Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
Rhea-AI Summary
Amphastar Pharmaceuticals (NASDAQ:AMPH) will present at the 2026 Bank of America Health Care Conference on May 13, 2026 at 3:00 pm PT. Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will discuss corporate strategy. The webcast is available at Amphastar's investor website and will remain online for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – AMPH
In the May 6 session, AMPH gained 2.18%, reflecting a moderate positive market reaction. Argus tracked a trough of -12.0% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Earnings date notice | Neutral | +1.5% | Scheduled Q1 2026 earnings release and investor conference call details. |
| Apr 06 | Conference presentation | Neutral | +0.6% | Planned presentation at Needham healthcare conference with webcast access. |
| Feb 26 | Earnings results | Positive | -23.6% | Reported strong Q4 and FY 2025 revenues, earnings, and cash flow metrics. |
| Feb 24 | FDA approval | Positive | +0.4% | FDA approval and 180-day exclusivity for Ipratropium Bromide HFA launch. |
| Feb 20 | Earnings date notice | Neutral | -0.0% | Announced timing and access details for Q4 2025 earnings call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Conference and scheduling announcements have historically led to modest price moves, while fundamental events like earnings and FDA approvals have produced larger, sometimes contrary, reactions (notably a sharp selloff on strong Q4/FY 2025 results).
Over the last six months, Amphastar reported multiple operational and financial milestones. An FDA approval for Ipratropium Bromide HFA with 180 days of generic exclusivity and several ANDA/biosimilar programs highlighted pipeline progress. Q4 and full-year 2025 results showed substantial net revenues of $183.1M for the quarter and $719.9M for the year, alongside strong cash flow, yet the stock declined 23.63% after that release. In contrast, prior conference and earnings-date announcements around February–April 2026 produced only modest price moves, similar in nature to today’s conference-presentation news.
Key Terms
forward-looking statements regulatory
annual report on form 10-k regulatory
securities and exchange commission regulatory
clinical trials medical
fda filings or approvals regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
About Amphastar Pharmaceuticals, Inc.
Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredients, or API products. Most of the Company's finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.
Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVY®, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Forward-Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth and our ability to continue to scale, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the impact of our products, including their potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our long-term strategic vision, our ability to leverage our existing expertise and technology, the impacts of any licensing agreements and ability to commercialize additional therapies, our in-house manufacturing expertise, our ability to deliver high quality, affordable therapies to patients, our commercial momentum and position in the market. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission ("SEC"), including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire